1 – 20 of 37
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Hormone receptor mRNA and protein levels as predictors of premenopausal tamoxifen benefit
(
- Contribution to journal › Article
- 2023
-
Mark
Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer : data from the randomized SBII:2 trial
(
- Contribution to journal › Article
-
Mark
Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
(
- Contribution to journal › Article
- 2022
-
Mark
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients
(
- Contribution to journal › Article
- 2021
-
Mark
Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer
(
- Contribution to journal › Article
- 2020
-
Mark
Expression of HGF, pMet, and pAkt is related to benefit of radiotherapy after breast-conserving surgery : a long-term follow-up of the SweBCG91-RT randomised trial
(
- Contribution to journal › Article
-
Mark
Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer : data from a randomised trial with long-term follow-up
(
- Contribution to journal › Article
- 2018
-
Mark
Non-linear transformations of age at diagnosis, tumor size, and number of positive lymph nodes in prediction of clinical outcome in breast cancer
(
- Contribution to journal › Article
-
Mark
Tumor PIK3CA genotype and prognosis in early-stage breast cancer : A pooled analysis of individual patient data
(
- Contribution to journal › Article
- 2017
-
Mark
Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen
(
- Contribution to journal › Article
-
Mark
Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013
(
- Contribution to journal › Article
- 2016
-
Mark
Two years of adjuvant tamoxifen provides a survival benefit compared with no systemic treatment in premenopausal patients with primary breast cancer : Long-Term follow-up (> 25 years) of the phase III SBII:2pre trial
(
- Contribution to journal › Article
- 2015
-
Mark
Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance.
(
- Contribution to journal › Article
-
Mark
Histological grade provides significant prognostic information in the discrimination between luminal A-like and luminal B-like HER-2 normal subtypes of breast cancer according to St Gallen 2013
(
- Contribution to journal › Published meeting abstract
- 2014
-
Mark
Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response.
(
- Contribution to journal › Article
-
Mark
Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.
(
- Contribution to journal › Article
- 2013
-
Mark
The prevalence of immunohistochemically determined oestrogen receptor positivity in primary breast cancer is dependent on the choice of antibody and method of heat-induced epitope retrieval - prognostic implications?
(
- Contribution to journal › Article
-
Mark
Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up
(
- Contribution to journal › Article
-
Mark
The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer.
(
- Contribution to journal › Article
- 2012
-
Mark
Low ERK Phosphorylation in Cancer-Associated Fibroblasts Is Associated with Tamoxifen Resistance in Pre-Menopausal Breast Cancer
(
- Contribution to journal › Article